Results 81 to 90 of about 161,983 (298)

Firing up the cold tumors by targeting Vps34

OncoImmunology, 2020
Cancer immunotherapy based on anti-PD-1/PD-L1 blockade is particularly effective in responding to patients with hot tumors. These tumors are characterized by the accumulation of proinflammatory cytokines and T cell infiltration.
Bassam Janji, Meriem Hasmim, Santiago Parpal, Guy Berchem, Muhammad Zaeem Noman   +4 more
doaj   +1 more source

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors

Frontiers in Oncology, 2023
BackgroundIn patients with cirrhosis, portal hypertension increases intestinal permeability, dysbiosis, and bacterial translocation, promoting an inflammatory state that can lead to the progression of liver disease and development of hepatocellular carcinoma (HCC).
Y. Linda Wu, Grace van Hyfte, Umut Özbek, Marlene Reincke, Anuhya Gampa, Yehia I. Mohamed, Naoshi Nishida, Brooke Wietharn, Suneetha Amara, Pei-Chang Lee, Bernhard Scheiner, Lorenz Balcar, Matthias Pinter, Arndt Vogel, Arndt Weinmann, Anwaar Saeed, Anjana Pillai, Lorenza Rimassa, Lorenza Rimassa, Abdul Rafeh Naqash, Mahvish Muzaffar, Yi-Hsiang Huang, Ahmed O. Kaseb, Masatoshi Kudo, David J. Pinato, Celina Ang   +25 more
openaire   +4 more sources

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Tumor Immunogenic Cell Death as a Mediator of Intratumor CD8 T-Cell Recruitment

Cells, 2022
The success of anticancer treatments relies on a long-term response which can be mediated by the immune system. Thus, the concept of immunogenic cell death (ICD) describes the capacity of dying cancer cells, under chemotherapy or physical stress, to ...
Nicolas Roussot, François Ghiringhelli, Cédric Rébé   +2 more
doaj   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

41P BRCA2 pathogenic variant (PV): A novel agnostic biomarker for immune checkpoint blockers (ICB)? [PDF]

, 2023
Beatriz Alonso de Castro, M.I. Gomez Randulfe, K. Ouali, K. Beshiri, Javier Gavira, C. Baldini, S. Champiat, Jean‐Marie Michot, R. Bahleda, F-X. Danlos, A. Gazzah, A. Hollebecque, A. Bayle, Y. Loriot, A. Varga, A. Marabelle, S. Postel-Vinay, S. Ponce Aix   +17 more
openalex   +1 more source

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

Molecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He, Chiara Testini, Neda Hekmati, Altea Bonello, Aglaia Schiza, Emmanuel Nwadozi, Mia Phillipson, Carina Strell, Michael Welsh   +8 more
wiley   +1 more source

Deubiquitinating Enzyme: A Potential Secondary Checkpoint of Cancer Immunity

Frontiers in Oncology, 2020
The efficacy of cancer immunotherapy depends on the fine interplay between tumoral immune checkpoints and host immune system. However, the up-to-date clinical performance of checkpoint blockers in cancer therapy revealed that higher-level regulation ...
Xing Huang, Xing Huang, Xing Huang, Xiaozhen Zhang, Xiaozhen Zhang, Xiaozhen Zhang, Jian Xu, Jian Xu, Jian Xu, Xun Wang, Xun Wang, Xun Wang, Gang Zhang, Gang Zhang, Gang Zhang, Tianyu Tang, Tianyu Tang, Tianyu Tang, Xiaochao Shen, Xiaochao Shen, Xiaochao Shen, Tingbo Liang, Tingbo Liang, Tingbo Liang, Xueli Bai, Xueli Bai, Xueli Bai   +26 more
doaj   +1 more source

The effect of blocking immune checkpoints LAG-3 and PD-1 on human invariant Natural Killer T cell function [PDF]

, 2023
Allison L. Balasko, Monika M. Kowatsch, Colin Graydon, Julie Lajoie, Keith R. Fowke   +4 more
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source